Beijing Immunochina Pharmaceuticals Co., Ltd.
http://www.immunochina.com/en/index/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Beijing Immunochina Pharmaceuticals Co., Ltd.
Cell Therapy Developers Dominate China VC/PE Funding In October
Six Chinese biotechs raise a combined $141m in major financing deals backed by venture capital and private equity firms.
Abogen and Neurophth Lead China mRNA, Gene And Cell Therapy Funding Rush
Total of $571m raised in China from 10 venture capital and private equity funding deals betting heavily on mRNA and targeted oncology, as well as gene and cell therapies.
Asia Deal Watch: Promethera Calls On Hao Tian For Asian JV To Advance Its Liver Candidates
Plus recent deals involving BeiGene, Assembly Biosciences, Piramal, Medivant, Revitope, Junshi, JW Therapeutics, Eureka, Acepodia, Chiesi, Bayer, NewG Lab, AnHeart
Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Immunochina Pharmaceuticals
- Immunochina Pharmaceuticals Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice